Transfuse: Symptomatic or Hb <70 g/L (<80 g/L with heart disease) — never delayed for a fully compatible unit
Key points
Warm AIHA responds to steroids in ~80% within 3 weeks, but most relapse on the taper — rituximab is the preferred second line; splenectomy is now third line.
Give folic acid 5 mg daily while haemolysing; thromboprophylaxis for inpatients with active haemolysis.
Long steroid courses (≥20 mg/day for >4 weeks, especially with rituximab): co-trimoxazole PJP prophylaxis, calcium + vitamin D, PPI if GI risk.
Always look for a secondary cause — about half of AIHA is secondary (lymphoproliferative disease, SLE, infection, drugs).
Never
Withhold blood in life-threatening anaemia because the crossmatch is "incompatible"
Expect steroids to work in cold agglutinin disease
Start rituximab without hepatitis B screening
Stop steroids abruptly
Common mistakes
Waiting for a compatible crossmatch in severe anaemia
Missing drug-induced haemolysis
Missing lymphoma, CLL or SLE behind "idiopathic" AIHA
Steroids for cold agglutinin disease
Stopping steroids too fast
Disposition and follow-up
Ward until Hb is stable; ICU for cardiac or neurological compromise. Haematology weekly during the taper and a search for a secondary cause.
ICU Decoded — original critical-care and internal-medicine pathways by
Dr Javed Akhtar, each cited to a current guideline. For education and quick
reference; verify every dose against local protocols before prescribing.